<span class="articleLocation”>A U.S. appeals court on Thursday ruled in favor
of Eli Lilly & Co in a closely-watched patent case,
saying a lower court judge correctly found Teva Pharmaceutical
Industries Ltd and other companies liable for inducing
the infringement of Lilly’s lung cancer drug Alimta.

The decision by the U.S. Federal Circuit Court of Appeals
came in a case in which Lilly sought to block Teva and other
defendants from launching generic versions of Alimta, one of its
best-selling drugs, before patent protections fully expire in
2022.